Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study

Wu, Jun-Zheng; Li, Cong-Lei; Shi, Haibin; Liu, Sheng; Yang, Wei; Zhou, Wei-Zhong

doi:10.1007/s11604-021-01212-7

Cited by 9 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the benefits of 125 I brachytherapy combined with arterial infusion chemotherapy also found in other cancers. [23–25] In this study, the 125 I brachytherapy combined with arterial infusion chemotherapy could achieve a median survival time of 13-month. LCR, median survival and survival rate were similar to previously reports.…”

Section: Discussionmentioning

confidence: 82%

Feasibility of 125I brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer

Huang,

Cao,

Wang

et al. 2023

Medicine

View full text Add to dashboard Cite

To evaluation the feasibility of Iodine-125 (¹²5I) brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer. A total of 72 cases with Stage III and IV were retrospectively reviewed. 23 cases receiving 125I brachytherapy were classified as Group A. 27 cases receiving arterial infusion chemotherapy (gemcitabine + cisplatin, GP) were classified as Group B and 22 cases receiving 125I brachytherapy combined with arterial infusion chemotherapy (GP) were classified as Group C. The evaluated indications were local control rate, survival rate, carbohydrate antigen 19-9, pain relief, and Karnofsky physical scores. Analysis of Variancep, Pearson chi-square test and Kaplan–Meier curves were used for analysis. The local control rate of group A and group C was significantly higher than group B (P < .001). Pearson chi-square test showed statistical difference of the 3 groups (χ2 = 12.969, P = .044). The median survival of group A,B and C was 9 months, 6 months and 13 months, respectively. The survival time of group C was significantly higher than group B (χ2 = 5.403, P = .020). The Log rank test showed statistical difference in the survival curve of the 3 groups (χ2 = 6.501, P = .039). The difference of carbohydrate antigen 19-9 decline percentage between group B and C group was statistically significant (χ2 = 5.959, P = .015). Patients in group A and group C relieved form pain after treatment with statistically significant (P < .001). Pain relief was much more effective in patients who received 125I brachytherapy. Karnofsky physical scores after treatment were statistically higher than those before treatment in each group (P < .001). 125I brachytherapy maybe one of the effective, safe and feasible alternative treatment of advanced pancreatic cancer. ¹²5I brachytherapy combined with arterial infusion chemotherapy was effective in the treatment of advanced pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 82%

Feasibility of 125I brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer

Huang,

Cao,

Wang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, a study conducted by Wu et al. revealed that SI therapy and hepatic artery infusion chemotherapy (HAIC) prolonged overall survival (OS) to 12 months ( 14 ). This combined treatment approach effectively reduced bilirubin levels and diminished tumor lesions.…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, long-term obstructive jaundice is alleviated, leading to improved liver function and extended survival time for patients (13). Moreover, a study conducted by Wu et al revealed that SI therapy and hepatic artery infusion chemotherapy (HAIC) prolonged overall survival (OS) to 12 months (14). This combined treatment approach effectively reduced bilirubin levels and diminished tumor lesions.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice

Lin,

Ke,

Chen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesTo evaluate the efficacy and safety of biliary stenting implantation with iodine-125 seed strand (SI) followed by hepatic artery infusion chemotherapy (HAIC) plus lenvatinib (Len) with programmed death-1 (PD-1) inhibitor for patients diagnosed with extrahepatic cholangiocarcinoma (ECC) and malignant obstructive jaundice (MOJ).MethodsIn this single-center retrospective study, the data of ECC patients with MOJ from March 2015 to January 2023 was assessed. Using probability score matching (PSM), the selection bias of patients was reduced. Primary study outcomes included overall survival (OS) and progression-free survival (PFS). The OS and PFS were performed using the Kaplan–Meier method and evaluated with the log-rank test.ResultsA total of 104 patients were enrolled finally, including 52 patients treated with interventional therapy (SI+HAIC) plus Len with PD-1 inhibitor (SI+HAIC+Len+P group) and 52 patients treated with interventional therapy (SI+HAIC) plus lenvatinib (SI+HAIC+Len group). 26 pairs of patients were matched after PSM analysis. After PSM analysis, the median OS and PFS in the SI+HAIC+Len+P group were significantly longer compared to those in the SI+HAIC+Len group (OS:16.6 vs. 12.3 months, P = 0.001; PFS:12.6 vs 8.5 months, P = 0.004). The DCR was significantly different between groups (P = 0.039), while ORR not (P = 0.548). The addition of PD-1 inhibitor was generally well tolerated without treatment-associated mortality.ConclusionInterventional therapy (SI+HAIC) plus Len with PD-1 inhibitor was effective for ECC patients accompanied by MOJ with a manageable safety profile.

show abstract

“…Malignant obstructive jaundice can cause many adverse events including severe cholangitis, lower the quality of life, and increase mortality, which can occur following pancreatic cancer, hilar cholangiocarcinoma, and periampullary carcinoma (1)(2)(3)(4). For advanced malignant obstructive jaundice (AMOJ) with no chance for radical cure, although combined treatment and local treatment are indispensable (5)(6)(7), effective and reliable biliary drainage is the most important palliative treatment (1-4, 8, 9). Percutaneous transhepatic biliary drainage (PTBD), endoscopic biliary drainage (EBD) and bilioenteric anastomosis are the commonly used clinical methods for AMOJ at present (2,9,10).…”

Section: Introductionmentioning

confidence: 99%

An alternative palliative surgical method for advanced malignant obstructive jaundice: Laparoscopic bridge choledochoduodenostomy

Luan

Hongsheng²,

Xuxiang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundThis study introduces an alternative palliative surgical procedure called laparoscopic bridge choledochoduodenostomy (LBCDD) for patients with advanced malignant obstructive jaundice (AMOJ).MethodsPatients with AMOJ who had LBCDD between January 2017 and August 2021 were identified from databases of two institutions in China.ResultsA total of 35 patients (male 12; female 23) with an average age of 64 years were enrolled. The average diameter of the tumor is 4.24 cm. All patients undertook LBCDD within an average operation time of 75 min with a mean blood loss of 32 ml. One patient had controlled bile leakage after the operation and two developed surgical site infection involving the epigastric orifices. All of them were solved by conservative treatment. All patients were discharged smoothly after an average hospital stay of 5.5 days, and no conversion to open surgery was required.ConclusionsLBCDD is a safe and efficient palliative surgery, which has a good therapeutic effect on patients with AMOJ.

show abstract

Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study

Cited by 9 publications

References 38 publications

Feasibility of 125I brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer

Feasibility of 125I brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer

Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice

An alternative palliative surgical method for advanced malignant obstructive jaundice: Laparoscopic bridge choledochoduodenostomy

Contact Info

Product

Resources

About